Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C15H14N4O
CAS Number:
Molecular Weight:
266.30
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
SMILES string
CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O
InChI key
NQDJXKOVJZTUJA-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
nevirapine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Related Categories
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Nevirapine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
NNRTI (non-nucleoside reverse transcriptase inhibitor) of HIV-1
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J Ena et al.
HIV medicine, 9(9), 747-756 (2008-07-25)
We performed a meta-analysis to assess the efficacy and safety of switching from protease inhibitor (PI)- to nevirapine (NVP)-based regimens in HIV-infected patients in whom virological suppression had been achieved. Six trials (550 patients) were analysed. The demographics showed that
Prinitha Pillay et al.
PloS one, 8(7), e68995-e68995 (2013-07-31)
There is conflicting evidence and practice regarding the use of the non-nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-line antiretroviral therapy (ART). We systematically reviewed virological outcomes in HIV-1 infected, treatment-naive patients on regimens containing EFV
J-J Parienti et al.
Medecine et maladies infectieuses, 40(9), 499-505 (2010-05-04)
Taking into account long-term adverse effects of antiretroviral treatment has become a major concern for physicians managing HIV infected patients. More specifically, cardiovascular risk is the fourth cause of death in this population. Nevirapine, when used in antiretroviral naive patients
Laveeza Bhatti et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 11(6), 369-373 (2012-08-30)
Nevirapine (NVP) was the first nonnucleoside reverse transcriptase inhibitor (NNRTI) approved by the US Food and Drug Administration (FDA) in 1996, for the treatment of HIV infection. Current treatment guidelines include NVP as a component of a recommended alternative NNRTI
Jean-Jacques Parienti et al.
Expert opinion on drug metabolism & toxicology, 7(4), 495-503 (2011-03-23)
Nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor, has been an important component of HIV infection treatment for many years. Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service